OBCI Pengajuan SEC - Ocean Bio-Chem, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

350737

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ocean Bio-Chem, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 19, 2022	15-12G	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 0-11102 (Commission File Number) OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in its
August 9, 2022	S-8 POS	As filed with the Securities and Exchange Commission on August 9, 2022 As filed with the Securities and Exchange Commission on August 9, 2022 Registration No.
August 9, 2022	EX-3.2	Bylaws of Ocean Bio-Chem, Inc., adopted August 9, 2022. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF OCEAN BIO-CHEM, INC. ARTICLE I Offices Section 1.01 Offices. The address of the registered office of Ocean Bio-Chem, Inc. (hereinafter called the ?Corporation?) in the State of Florida shall be the address listed as such in the Corporation?s Articles of Incorporation, as the same may be amended from time to time (the ?Articles of Incorporation?), which is
August 9, 2022	S-8 POS	As filed with the Securities and Exchange Commission on August 9, 2022 As filed with the Securities and Exchange Commission on August 9, 2022 Registration No.
August 9, 2022	S-8 POS	As filed with the Securities and Exchange Commission on August 9, 2022 As filed with the Securities and Exchange Commission on August 9, 2022 Registration No.
August 9, 2022	8-K	Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2022 (August 9, 2022) OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in its charter) Florida 0-11102 59-1564329 (State or other jurisdiction of incorporation) (
August 9, 2022	S-8 POS	As filed with the Securities and Exchange Commission on August 9, 2022 As filed with the Securities and Exchange Commission on August 9, 2022 Registration No.
August 9, 2022	S-8 POS	As filed with the Securities and Exchange Commission on August 9, 2022 As filed with the Securities and Exchange Commission on August 9, 2022 Registration No.
August 9, 2022	EX-3.1	Articles of Incorporation of Ocean Bio-Chem, Inc., adopted August 9, 2022. Exhibit 3.1 2 3 4 5 6
August 9, 2022	S-8 POS	As filed with the Securities and Exchange Commission on August 9, 2022 S-8 POS 1 ea163953-s8posoceanbiochem.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on August 9, 2022 Registration No. 333-112440 Registration No. 333-127837 Registration No. 333-139603 Registration No. 333-146893 Registration No. 333-174659 Registration No. 333-176268 Registration No. 333-204520 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 205
August 9, 2022	S-8 POS	As filed with the Securities and Exchange Commission on August 9, 2022 As filed with the Securities and Exchange Commission on August 9, 2022 Registration No.
August 9, 2022	SC 13D/A	OBCI / Ocean Bio-Chem, Inc. / OneWater Marine Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ocean Bio-Chem, Inc. (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 674631106 (CUSIP Number) Philip Austin Singleton Chief Executive Officer OneWater Marine Inc. 6275 Lanier Islands Parkway Buford, Georgia 30518
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, INC. (E
July 11, 2022	DEFM14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement OCEAN BIO-CHEM, INC. (Name of Regist
July 1, 2022	SC 13D	OBCI / Ocean Bio-Chem, Inc. / OneWater Marine Inc. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Ocean Bio-Chem, Inc. (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 674631106 (CUSIP Number) Philip Austin Singleton Chief Executive Officer OneWater Marine Inc. 6275 Lanier Islands Parkway Buford, Georgia 30518 (678) 541-6300 with
July 1, 2022	PREM14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement OCEAN BIO-CHEM, INC. (Name of Regist
July 1, 2022	EX-FILING FEES	Calculation of Filing Fee Tables Schedule 14C Ocean Bio-Chem, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Exhibit 107 Calculation of Filing Fee Tables Schedule 14C Ocean Bio-Chem, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fees to Be Paid(1) $124,388,171 0.0000927 $11,531 Fees Previously Paid Total Transaction Valuation $124,388,171 Total Fees Due for Filing $11,531 Total Fees
June 22, 2022	EX-2.1	Agreement and Plan of Merger, dated as of June 21, 2022, by and among Ocean Bio-Chem, Inc., OneWater Marine Inc. and OBCMS, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 22, 2022). Exhibit 2.1 Execution Version Confidential AGREEMENT AND PLAN OF MERGER by and among ONEWATER MARINE INC., OBCMS, INC. and OCEAN BIO-CHEM, INC. Dated as of June 21, 2022 TABLE OF CONTENTS ARTICLE I The Merger 2 Section 1.01 The Merger 2 Section 1.02 Closing 2 Section 1.03 Effective Time 2 Section 1.04 Effects of the Merger 2 Section 1.05 Articles of Incorporation; Bylaws 2 Section 1.06 Directors a
June 22, 2022	8-K	Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2022 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in its charter) Florida 0-11102 59-1564329 (State or other jurisdiction of incorporation) (Commission File Nu
June 22, 2022	EX-99.1	OneWater Marine Inc. Signs Definitive Agreement to Acquire Ocean Bio-Chem, Inc. Expected to significantly advance growth of parts and accessories business Exhibit 99.1 OneWater Marine Inc. Signs Definitive Agreement to Acquire Ocean Bio-Chem, Inc. Expected to significantly advance growth of parts and accessories business BUFORD, GA and FT. LAUDERDALE, FL June 22, 2022 - OneWater Marine Inc. (NASDAQ: ONEW) (?OneWater? or the ?Company?) announced today that it has signed a definitive agreement to acquire Ocean Bio-Chem, Inc. (NASDAQ: OBCI) (?OBCI? or
June 7, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 27, 2022	8-K/A	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 27, 2022 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 4041 S.W.
May 26, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 25, 2022 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 4041 S.W. 47
May 19, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 19, 2022	EX-99.1	Ocean Bio-Chem, Inc. Announces First Quarter 2022 Financial Results Exhibit 99.1 Ocean Bio-Chem, Inc. Announces First Quarter 2022 Financial Results Star brite Inc. Parent Company Reports First Quarter Net Sales of $12.7 Million and Net Income of $1.3 Million FORT LAUDERDALE, FL, May 16, 2022 ? Ocean Bio-Chem, Inc. (NASDAQ: OBCI), the parent company of Star brite Inc. and Kinpak Inc. ? vertical manufacturer and distributor of performance, appearance, maintenance,
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, INC. (
April 20, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 11, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 1, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 1, 2022	EX-99.1	2 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Fourth Quarter and Full Year 2021 Net Sales, Net Income, and Earnings per Share Star brite parent announces net sales of $64.3 million highest in company history?15.7% higher than 2020?and net income of $8.4 million FORT LAUDERDALE, FL, March 31, 2022 ? Ocean Bio-Chem, Inc. (NASDAQ: OBCI), the parent company of Star brite Inc. and Kinpak Inc.?vertical manu
March 31, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-11102 OCEAN BIO-CHEM, INC. (Exac
March 31, 2022	EX-21	List of Subsidiaries EXHIBIT 21 The following is a list of the Registrant?s subsidiaries: Name Jurisdiction of Organization Ownership % Star-brite Distributing, Inc.
February 28, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 28, 2022 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 4041 S.
February 28, 2022	EX-99.1	OCEAN BIO-CHEM, INC. ANNOUNCES A 33 PERCENT INCREASE IN REGULAR QUARTERLY DIVIDEND EXHIBIT 99.1 OCEAN BIO-CHEM, INC. ANNOUNCES A 33 PERCENT INCREASE IN REGULAR QUARTERLY DIVIDEND FORT LAUDERDALE, Fla., Feb. 28, 2022 /PRNewswire/ - Ocean Bio-Chem, Inc. (NASDAQ: OBCI), the premier manufacturer and distributor for specialty chemicals in the marine, automotive, recreational vehicle and home care markets, today announced that the Company?s Board of Directors approved a quarterly regu
January 20, 2022	EX-99.1	Ocean Bio-Chem, Inc. Reports Another Quarter and Year of Record Net Sales for Q4 and Full Year 2021 EXHIBIT 99.1 Ocean Bio-Chem, Inc. Reports Another Quarter and Year of Record Net Sales for Q4 and Full Year 2021 The Star brite Parent Sees Sales More than Double in Nine Years FORT LAUDERDALE, FL, January 18, 2022 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today record net sales for both the fourth quarter and the full year 2021, continuing a 9-year trend of record-breaking sales. 2021 Highl
January 20, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 19, 2022 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 4041 S.W
November 23, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 16, 2021	EX-99.1	Ocean Bio-Chem, Inc. Reports Third Quarter and Nine Month Financial Results for 2021 EXHIBIT 99.1 Ocean Bio-Chem, Inc. Reports Third Quarter and Nine Month Financial Results for 2021 Third-quarter 2021?Net Sales up 12% to $21.5 million. Earnings $0.34 per share Nine Months 2021?Net Sales up 18% to $50.3 million. $0.82 Earnings per share FORT LAUDERDALE, FL, November 15, 2021 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI), a leader in performance and appearance chemicals, released its third
November 16, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, IN
August 27, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2021. OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Num
August 16, 2021	EX-10.2	Guaranty Agreement dated July 20, 2021, provided by the Company to Regions (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021). Exhibit 10.2 GUARANTY AGREEMENT THIS GUARANTY AGREEMENT (?this Agreement?), made as of the th day of July, 2021 by Ocean Bio-Chem, Inc., a Florida corporation (the ?Guarantor?) with Regions Bank, an Alabama banking corporation (the ?Bank?). W I T N E S S E T H: WHEREAS, Kinpak Inc., an Alabama corporation (the ?Borrower?), has executed and delivered to Bank a certain Promissory Note dated July 20,
August 16, 2021	EX-10.3	Business Loan Agreement effective July 30, 2021 between the Company and Regions (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021). Exhibit 10.3 DOC11503000002302960300000009990000000 BUSINESS LOAN AGREEMENT (ASSET BASED) Principal $6,000,000.00 Loan Date 07-30-2021 Maturity 08-30-2024 Bank/App 01 Loan No 00230296030000000999 Account 0023029603 Officer K9GP4 References in the shaded area are for Lender?s use only and do not limit the applicability of this document to any particular loan or item. Any item above containing ?**
August 16, 2021	EX-10.1	Credit Agreement dated July 20, 2021, between Kinpak and Regions (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021). Exhibit 10.1 CREDIT AGREEMENT THIS CREDIT AGREEMENT is made and entered into this 20th day of July 2021, by and between: Kinpak Inc., an Alabama Corporation (hereinafter ?Borrower?); and Regions Bank, an Alabama banking corporation (hereinafter referred to as the ?Bank?). W I T N E S S E T H: WHEREAS, Borrower has a plant location in Montgomery, Alabama located in the Industrial Development Park a
August 16, 2021	EX-10.4	Commercial Security Agreement dated July 30, 2021 between the Company and Regions (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021). Exhibit 10.4 DOC17003000002302960300000009990000000 COMMERCIAL SECURITY AGREEMENT Principal $6,000,000.00 Loan Date 07-30-2021 Maturity 08-30-2024 Bank/App 01 Loan No 00230296030000000999 Account 0023029603 Officer K9GP4 References in the shaded area are for Lender?s use only and do not limit the applicability of this document to any particular loan or item. Any item above containing ?***? has b
August 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, INC. (E
August 12, 2021	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2021 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in its charter) Florida 0-11102 59-1564329 (State or other jurisdiction of incorporation or organization) (C
August 4, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2021 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in its charter) Florida 0-11102 59-1564329 (State or other jurisdiction of incorporation or organization) (Co
July 27, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 27, 2021 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 4041 S.W. 4
July 27, 2021	EX-99.1	Ocean Bio-Chem, Inc. Reports Record Net Sales for the First Six Months of 2021—23% Increase Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Record Net Sales for the First Six Months of 2021?23% Increase FORT LAUDERDALE, FL, July 27, 2021 ? Ocean Bio-Chem, Inc. (NASDAQ: OBCI), the parent company of Star brite, Inc. and Kinpak, Inc.?vertical manufacturer and distributor of performance, appearance, maintenance, and disinfectant chemicals for the marine, RV, and outdoor industries?is pleased to an
June 23, 2021	EX-99.1	PERFORMACIDE® Kills Virus Causing COVID-19 In Just 30 Seconds Exhibit 99.1 PERFORMACIDE? Kills Virus Causing COVID-19 In Just 30 Seconds PERFORMACIDE? Disinfectant Gets New EPA Label After Successful SARS-CoV-2 Testing FORT LAUDERDALE, FL, June 22, 2021 ? OdorStar Technology, LLC. a subsidiary of Ocean Bio-Chem, Inc. (NASDAQ: OBCI), announces it has received approval from The U.S. Environmental Protection Agency (EPA) for its PERFORMACIDE? brand of disinfect
June 23, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number
June 7, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 24, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2021. OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 20, 2021	EX-99.1	Ocean Bio-Chem, Inc. Announces Record First Quarter 2021 Financial Results EXHIBIT 99.1 Ocean Bio-Chem, Inc. Announces Record First Quarter 2021 Financial Results Star brite Parent Company Reports First Quarter Net Sales of $13.1 Million up 68%, and Net Income of $1.9 Million up 204% FORT LAUDERDALE, Fla., May 17, 2021 /PRNewswire/ - Ocean Bio-Chem, Inc. (NASDAQ: OBCI), the parent company of Star brite, Inc. and Kinpak, Inc. ? vertical manufacturer and distributor of per
May 20, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 14, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, INC. (
May 7, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 30, 2021	DEF 14A	- DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)
April 20, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 19, 2021 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 4041 S.W.
April 20, 2021	EX-99.1	Ocean Bio-Chem, Inc. Reports Record 2021 First Quarter Net Sales - Increase of 68% or $5.3 million Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Record 2021 First Quarter Net Sales - Increase of 68% or $5.3 million FORT LAUDERDALE, FL, April 19, 2021 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI), parent of Star brite, Inc., announced today record net sales for the first quarter of 2021. For the first quarter of 2021, net sales were approximately $13.1 million, compared to approximately $7.8 million for the
April 1, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021. OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numb
April 1, 2021	EX-99.1	Ocean Bio-Chem, Inc. Reports Record 2020 Year Net Sales, Income, and Earnings per Share Announces $9.6 Million in Net Income, highest in Company history and 175% higher than 2019 EXHIBIT 99.1 Ocean Bio-Chem, Inc. Reports Record 2020 Year Net Sales, Income, and Earnings per Share Announces $9.6 Million in Net Income, highest in Company history and 175% higher than 2019 FORT LAUDERDALE, FL, March 29, 2021 ? Ocean Bio-Chem, Inc. (NASDAQ: OBCI), the parent company of Star brite, Inc. and Kinpak Inc.?vertical manufacturer and distributor of performance, appearance, maintenance,
March 29, 2021	10-K	Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-11102 OCEAN BIO-CHEM, INC. (Exac
March 29, 2021	EX-21	List of Subsidiaries EXHIBIT 21 The following is a list of the Registrant?s subsidiaries: Name Jurisdiction of Organization Ownership % Star-brite Distributing, Inc.
March 2, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021. OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 2, 2021	EX-99.1	Ocean Bio-Chem, Inc. Announces Annual Regular Cash Dividend Increase of 50% to $0.12 per share EX-99.1 2 ea136844-ex991oceanbiochem.htm OCEAN BIO-CHEM, INC. ANNOUNCES ANNUAL REGULAR CASH DIVIDEND EXHIBIT 99.1 Ocean Bio-Chem, Inc. Announces Annual Regular Cash Dividend Increase of 50% to $0.12 per share FORT LAUDERDALE, FL, March 1, 2021 – Ocean Bio-Chem, Inc. (NASDAQ: OBCI), parent company of Star brite, Inc.—vertical manufacturer and distributor of performance, appearance, and maintenance
February 4, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No.1 Under the Securities Exchange Act of 1934 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No.1 Under the Securities Exchange Act of 1934 OCEAN BIO-CHEM, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 674631106 (CUSIP Number) January 29, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
February 3, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Num
February 3, 2021	EX-99.1	Ocean Bio-Chem, Inc. (OBCI) Subsidiary, Kinpak Inc, Announces $5 Million Expansion of its Manufacturing & Distribution Facility in Montgomery, AL. EX-99.1 2 ea134541ex99-1ocean.htm FEBRUARY 2, 2021 Exhibit 99.1 Ocean Bio-Chem, Inc. (OBCI) Subsidiary, Kinpak Inc, Announces $5 Million Expansion of its Manufacturing & Distribution Facility in Montgomery, AL. Ø The subsidiary Star brite, Inc. 2020 sales growth of 32% to $55.6 million initiated the planned capital expansion for future sales growth. FORT LAUDERDALE, FL (PRNewswire - February 2, 20
January 25, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2021. OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
January 25, 2021	EX-99.1	Ocean Bio-Chem, Inc. Reports Record Net Sales for both the Fourth Quarter and the Full Year of 2020, both up 32% Starts year with record $7.0 million in 2021 open sales orders EX-99.1 2 ea133852ex99-1oceanbio.htm PRESS RELEASE, DATED JANUARY 19, 2021 EXHIBIT 99.1 Ocean Bio-Chem, Inc. Reports Record Net Sales for both the Fourth Quarter and the Full Year of 2020, both up 32% Starts year with record $7.0 million in 2021 open sales orders FORT LAUDERDALE, Fl., January 19, 2021 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today record net sales for both the fourth quarte
November 25, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2020 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 25, 2020	EX-99.1	Ocean Bio-Chem, Inc. Board Authorizes Up to $3 Million Share Common Stock Repurchase Program EXHIBIT 99.1 Ocean Bio-Chem, Inc. Board Authorizes Up to $3 Million Share Common Stock Repurchase Program FORT LAUDERDALE, Fl., November 23 2020 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today that its Board of Directors has unanimously authorized a program to repurchase shares of the Company’s Common Stock, par value $0.01 per share (the “Common Stock”) constituting, in the aggregate, up to
November 13, 2020	10-Q	Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, IN
October 20, 2020	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2020 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File N
October 20, 2020	EX-99.1	Ocean Bio-Chem, Inc. Reports Record Net Sales ØThird Quarter of 2020 - 53% increase compared to Third Quarter of 2019 ØFirst Nine Months of 2020 - 31% increase compared to the first nine months of 2019 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Record Net Sales ØThird Quarter of 2020 - 53% increase compared to Third Quarter of 2019 ØFirst Nine Months of 2020 - 31% increase compared to the first nine months of 2019 FORT LAUDERDALE, Fl., October 19, 2020 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today record net sales for both the third quarter and first nine months of 2020. For the third qua
August 26, 2020	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2020 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 14, 2020	10-Q	Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, INC. (E
August 10, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 10, 2020	EX-99.1	Ocean Bio-Chem, Inc. Reports Record Income and Sales >Record Second Quarter 2020 - Net Income of $ 3.5 million an increase of 242% Diluted EPS of $0.36 compared to $0.11 § 227% increase > Record Six Month 2020 - Net income of $4.1 million an increase EXHIBIT 99.1 Ocean Bio-Chem, Inc. Reports Record Income and Sales >Record Second Quarter 2020 - Net Income of $ 3.5 million an increase of 242% Diluted EPS of $0.36 compared to $0.11 § 227% increase > Record Six Month 2020 - Net income of $4.1 million an increase of 136% Diluted EPS of $0.43 compared to $0.18 § 138% increase FORT LAUDERDALE, FL, August 10, 2020) – Ocean Bio-Chem, Inc. (NASDAQ: OBC
July 20, 2020	EX-99.1	Ocean Bio-Chem, Inc. Reports Record Net Sales for both the Second Quarter, 44% increase and the First Six Months of 2020, 18% increase Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Record Net Sales for both the Second Quarter, 44% increase and the First Six Months of 2020, 18% increase FORT LAUDERDALE, Fl., July 14, 2020 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today record net sales for the second quarter and the first six months of 2020. For the second quarter of 2020, net sales were approximately $15.7 million, compared to
July 20, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2020 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number
July 7, 2020	SC 13G	OBCI / Ocean Bio-Chem, Inc. / HIRSCHMAN ORIN - SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 OCEAN BIO-CHEM, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 674631106 (CUSIP Number) June 26, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
June 1, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2020 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 28, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2020 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 18, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2020 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 18, 2020	EX-99.1	Ocean Bio-Chem, Inc. Reports First Quarter 2020 Results First Quarter Net Sales of $7.8 Million, and Net Income of $627,000 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports First Quarter 2020 Results First Quarter Net Sales of $7.8 Million, and Net Income of $627,000 FORT LAUDERDALE, FL., May 15, 2020 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its first quarter 2020 financial results. For the first quarter of 2020, the Company reported net sales of approximately $7.8 million, a decrease of approximately $1.3 millio
May 15, 2020	10-Q	Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, INC. (
April 30, 2020	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2020 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 30, 2020	EX-99.1	Ocean Bio-Chem, Inc. Granted Additional Patent from U.S. Patent and Trademark Office for Disinfectant/Sanitizer Pouch Delivery System for Performacide® Performacide® included on EPA’s list of products qualified for use against virus that causes COVID EXHIBIT 99.1 Ocean Bio-Chem, Inc. Granted Additional Patent from U.S. Patent and Trademark Office for Disinfectant/Sanitizer Pouch Delivery System for Performacide® Performacide® included on EPA’s list of products qualified for use against virus that causes COVID-19 FORT LAUDERDALE, Fla., April 27, 2020 /PRNewswire/ - Ocean Bio-Chem, Inc. (NASDAQ: OBCI), has announced that its wholly owned subsidi
April 30, 2020	EX-10.1	Promissory note providing for the SBA Loan. Exhibit 10.1 1 2 3
April 30, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2020 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 29, 2020	DEF 14A	- DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)
March 30, 2020	10-K	OBCI / Ocean Bio-Chem, Inc. 10-K - Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-11102 OCEAN BIO-CHEM, INC. (Exac
March 30, 2020	EX-21	List of Subsidiaries EXHIBIT 21 The following is a list of the Registrant’s subsidiaries: Name Jurisdiction of Organization Ownership % Star-brite Distributing, Inc.
March 30, 2020	EX-4	Description of Common Stock (incorporated by reference to Exhibit 4 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019). Exhibit 4 DESCRIPTION OF COMMON STOCK General Ocean Bio-Chem, Inc. (“we,” “us,” “our,” or the “Company”) is authorized to issue 12,000,000 shares of common stock, par value $0.01 per share (the “Common Stock”). The transfer agent and registrar for the Common Stock is Computershare Trust Company, N.A., Meidinger Tower, 462 S. 4th Street, Louisville, KY 40202, telephone: (800) 522-6645. The Common S
March 23, 2020	EX-99.1	Ocean Bio-Chem, Inc. Announces Expansion of Production Capacity for Performacide® ,which is on the EPA’s List N: Disinfectants for Use Against SARS-CoV-2 Exhibit 99.1 Ocean Bio-Chem, Inc. Announces Expansion of Production Capacity for Performacide® ,which is on the EPA’s List N: Disinfectants for Use Against SARS-CoV-2 FORT LAUDERDALE, Fla., March 19, 2020 /PRNewswire/ - Ocean Bio-Chem, Inc. (NASDAQ: OBCI), has announced that its subsidiary manufacturing plant, Kinpak Inc. in Montgomery, Alabama has increased its number of shifts and is actively hi
March 23, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2020 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
January 30, 2020	8-K	Financial Statements and Exhibits, Other Events 8-K 1 f8k013020oceanbio.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2020 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdic
January 30, 2020	EX-99.1	OCEAN BIO-CHEM, INC. SUBSIDIARY STAR BRITE, INC. ANNOUNCES REGISTERED EPA PRODUCT KILLS THE CORONAVIRUS Exhibit 99.1 OCEAN BIO-CHEM, INC. SUBSIDIARY STAR BRITE, INC. ANNOUNCES REGISTERED EPA PRODUCT KILLS THE CORONAVIRUS FORT LAUDERDALE, Fla., January 27, 2020 — Ocean Bio-Chem, Inc. (NASDAQ: OBCI) today announced that its’ subsidiary Star brite Inc. product PERFORMACIDE® is registered with the U.S. Environmental Protection Agency (EPA) as a virucide effective against coronavirus, when used as direct
November 19, 2019	EX-99.1	Ocean Bio-Chem, Inc. Reports Third Quarter and Nine Month Financial Results EX-99.1 2 f8k111419ex99-1oceanbio.htm PRESS RELEASE, DATED NOVEMBER 14, 2019 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Third Quarter and Nine Month Financial Results FORT LAUDERDALE, FL., November 14, 2019 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its financial results for the third quarter and the first nine months of 2019. For the three months ended September 30, 2019, net sales were
November 19, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 14, 2019	10-Q	OBCI / Ocean Bio-Chem, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, IN
August 15, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2019 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 15, 2019	EX-99.1	Ocean Bio-Chem, Inc. Reports Second Quarter and Six Month 2019 Results EXHIBIT 99.1 Ocean Bio-Chem, Inc. Reports Second Quarter and Six Month 2019 Results FORT LAUDERDALE, FL, August 14, 2019 – Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its financial results for the second quarter and first six months of 2019. For the second quarter of 2019, net sales were approximately $10.9 million, compared to net sales of approximately $11.4 million in the second quarter
August 14, 2019	10-Q	OBCI / Ocean Bio-Chem, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, INC. (E
June 24, 2019	8-K/A	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2019 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Com
June 6, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2019 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 15, 2019	10-Q	OBCI / Ocean Bio-Chem, Inc. 10-Q Quarterly Report QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, INC. (
May 2, 2019	DEFR14A	OBCI / Ocean Bio-Chem, Inc. DEFR14A DEFINITIVE REVISED PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e
April 30, 2019	DEF 14A	OBCI / Ocean Bio-Chem, Inc. DEF 14A DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(
April 1, 2019	S-8 POS	OBCI / Ocean Bio-Chem, Inc. POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 As filed with the Securities and Exchange Commission on April 1, 2019 Registration No.
April 1, 2019	S-8 POS	OBCI / Ocean Bio-Chem, Inc. POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 As filed with the Securities and Exchange Commission on April 1, 2019 Registration No.
March 29, 2019	EX-21	List of Subsidiaries EXHIBIT 21 The following is a list of the Registrant’s subsidiaries: Name Jurisdiction of Organization Ownership % Star brite Distributing, Inc.
March 29, 2019	10-K	OBCI / Ocean Bio-Chem, Inc. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-11102 OCEAN BIO-CHEM, INC. (Exac
March 26, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2019 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
November 15, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2018 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 15, 2018	EX-99.1	49% Increase in Third Quarter Net Income Ø Third quarter of 2018 Net Sales of $13.2 Million, an increase of $1.8 Million or 16.3% Over the Third Quarter of 2017 Ø Third Quarter of 2018 Net Income of $1.3 Million, an Increase of $419,000 or 49.1% Over Exhibit 99.1 49% Increase in Third Quarter Net Income Ø Third quarter of 2018 Net Sales of $13.2 Million, an increase of $1.8 Million or 16.3% Over the Third Quarter of 2017 Ø Third Quarter of 2018 Net Income of $1.3 Million, an Increase of $419,000 or 49.1% Over the Third Quarter of 2017 Ø Nine months Net Income a Record $2.9 Million, an Increase of $607,000 or 26.3% Over the 2017 period Ø Nine m
November 14, 2018	EX-10.1.1	Business Loan Agreement, dated August 31, 2018, between the Company and Regions Bank (the “Business Loan Agreement”) (incorporated by reference to Exhibit 10.1.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018). Exhibit 10.1.1
November 14, 2018	10-Q	OBCI / Ocean Bio-Chem, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, IN
November 14, 2018	EX-10.1.2	Promissory Note, dated August 31, 2018, issued by the Company to Regions Bank in connection with the revolving line of credit under the Business Loan Agreement (the “Promissory Note”) (incorporated by reference to Exhibit 10.1.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018). Exhibit 10.1.2
November 14, 2018	EX-10.1.3	Letter, dated August 31, 2018, from Regions Bank to the Company, regarding certain terms under the Business Loan Agreement and the Promissory Note (incorporated by reference to Exhibit 10.1.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018). Exhibit 10.1.3 August 31, 2018 Mr. Jeffrey Barocas Ocean Bio-Chem, Inc. 4041 S.W. 47 Ave. Ft. Lauderdale, FL 33314 Dear Jeff: The purpose of this letter is to document an agreement between Ocean Bio-Chem, Inc. and Regions Bank regarding specific terms and conditions relating to the renewal of a $6,000,000 line of credit. The terms presented below will supersede any conflicting language in the Prom
November 13, 2018	8-K/A	Regulation FD Disclosure, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2018 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (C
September 7, 2018	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2018 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 14, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2018 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 14, 2018	EX-99.1	Ocean Bio-Chem, Inc. Reports Record Second Quarter 2018 Net Income and Net Sales Second Quarter Net Income of $1.1 Million, an 18% Increase Over the Prior Year Period Second Quarter Net Sales of $11.4 Million, a 19% Increase Over the Prior Year Perio EXHIBIT 99.1 Ocean Bio-Chem, Inc. Reports Record Second Quarter 2018 Net Income and Net Sales Second Quarter Net Income of $1.1 Million, an 18% Increase Over the Prior Year Period Second Quarter Net Sales of $11.4 Million, a 19% Increase Over the Prior Year Period FORT LAUDERDALE, FL-(PRNewswire - August 14, 2018) – Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its financial results for the
August 14, 2018	10-Q	OBCI / Ocean Bio-Chem, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, INC. (E
August 7, 2018	EX-99.1	Ocean Bio-Chem, Inc. Announces the Acquisition of Snappy Marine, Inc. Exhibit 99.1 Ocean Bio-Chem, Inc. Announces the Acquisition of Snappy Marine, Inc. FORT LAUDERDALE, Fl., August 6, 2018 -Ocean Bio-Chem, Inc. (NASDAQ: OBCI) subsidiary Star brite Distributing, Inc. announces the acquisition of Snappy Marine, Inc. a leading manufacturer and distributor of teak care products, for the marine industry. Peter Dornau, President and CEO commented: “We started looking at
August 7, 2018	8-K	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2018 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
May 24, 2018	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2018 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 16, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2018 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 16, 2018	EX-99.1	Ocean Bio-Chem, Inc. Reports Record First Quarter Sales of $8.4 Million; and Net Income of $523,000 and Diluted EPS of $0.06 for the First Quarter of 2018 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Record First Quarter Sales of $8.4 Million; and Net Income of $523,000 and Diluted EPS of $0.06 for the First Quarter of 2018 FORT LAUDERDALE, FL., May 15, 2018 -Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its first quarter 2018 financial results. The Company reported record first quarter 2018 net sales of $8.4 million compared to net sales of appr
May 15, 2018	10-Q	OBCI / Ocean Bio-Chem, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, INC. (
May 7, 2018	DEFA14A	OBCI / Ocean Bio-Chem, Inc. DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)
May 1, 2018	EX-16	Letter of EisnerAmper LLP, dated May 1, 2018 EX-16 2 f8k042618ex16oceanbio.htm LETTER OF EISNERAMPER LLP, DATED MAY 1, 2018 EXHIBIT 16 May 1, 2018 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated April 26, 2018 of Ocean Bio-Chem, Inc. and are in agreement with the statements contained therein as it regards our firm. We have no basis to agree or disagree
May 1, 2018	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2018 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 16, 2018	DEF 14A	OBCI / Ocean Bio-Chem, Inc. DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(
April 3, 2018	EX-99.1	Ocean Bio-Chem, Inc. Reports 2017 - Full Year and Fourth Quarter Net Income and Net Sales 2017 Record Net Income of $2.6 Million – 24% increase over 2016 2017 Record Net Sales of $38.9 Million – 7.5% increase over 2016 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports 2017 - Full Year and Fourth Quarter Net Income and Net Sales 2017 Record Net Income of $2.6 Million – 24% increase over 2016 2017 Record Net Sales of $38.9 Million – 7.5% increase over 2016 FORT LAUDERDALE, Fl., April 2, 2018 -Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced its full year and fourth quarter 2017 financial results. The Company’s 2017 net incom
April 3, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2018 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 30, 2018	EX-21	List of Subsidiaries EXHIBIT 21 The following is a list of the Registrant’s subsidiaries: Name Jurisdiction of Organization Ownership % Star brite Distributing, Inc.
March 30, 2018	EX-10.1.4	Letter, dated December 20, 2017, from Regions Bank to the Company, regarding certain terms of the Business Loan Agreement. Exhibit 10.1.4
March 30, 2018	10-K	OBCI / Ocean Bio-Chem, Inc. ANNUAL REPORT (Annual Report) 10-K 1 f10k2017oceanbiochem.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi
March 21, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2018 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
January 18, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 f8k011718oceanbiochem.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2018 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Juri
January 18, 2018	EX-99.1	Ocean Bio-Chem, Inc. Reports Record 2017 & Fourth Quarter 2017 Net Sales and Prospects for 2018 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Record 2017 & Fourth Quarter 2017 Net Sales and Prospects for 2018 FORT LAUDERDALE, Fl., January 17, 2018 -Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today record 2017 net sales of approximately $38.9 million, compared to approximately $36.2 million for the full year of 2016, an increase of $2.7 million or 7.5%. For the fourth quarter of 2017, record ne
November 14, 2017	EX-10.1	Business Loan Agreement, dated August 31, 2017, between the Company and Regions Bank (the “Business Loan Agreement”). Exhibit 10.1 BUSINESS LOAN AGREEMENT (ASSET BASED) Principal Loan Date Maturity Bank/App Loan No Account Officer $6,000,000.00 08-31-2017 08-31-2018 01 00230296030000000999 0023029603 K9GP4 References in the shaded area are for Lender’s use only and do not limit the applicability of this document to any particular loan or item. Any item about containing “***” has been omitted due to text length li
November 14, 2017	EX-99.1	2 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Third Quarter and Nine Month Financial Results The Company achieved record net sales and record net income for the first nine months of the year despite the adverse impact of Hurricanes Harvey and Irma on third quarter 2017 results FORT LAUDERDALE, Fl., November 14, 2017 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its third quarter 2017 and first
November 14, 2017	10-Q	OBCI / Ocean Bio-Chem, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, IN
November 14, 2017	EX-10.2	Promissory Note, dated August 31, 2017, issued by the Company to Regions Bank in connection with the revolving line of credit under the Business Loan Agreement (the “Promissory Note”). Exhibit 10.2 PROMISSORY NOTE Principal Loan Date Maturity Bank/App Loan No Account Officer $6,000,000.00 08-31-2017 08-31-2018 01 00230296030000000999 0023029603 K9GP4 References in the shaded area are for Lender’s use only and do not limit the applicability of this document to any particular loan or item. Any item about containing “***” has been omitted due to text length limitations. Borrower: O
November 14, 2017	EX-10.3	Letter, dated August 31, 2017, from Regions Bank to the Company, regarding certain terms under the Business Loan Agreement and the Promissory Note. Exhibit 10.3 August 31, 2017 Mr. Jeffrey Barocas Ocean Bio-Chem, Inc. 4041 S.W. 47 Ave. Ft. Lauderdale, FL 33314 Dear Jeff: The purpose of this letter is to document an agreement between Ocean Bio-Chem, Inc. and Regions Bank regarding specific terms and conditions relating to the renewal (and increase of) a $4,000,000 line of credit (now $6,000,000). The terms presented below will supersede any co
November 14, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2017 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
October 2, 2017	EX-99.2	SECOND RESTATED LEASE AGREEMENT THE INDUSTRIAL DEVELOPMENT BOARD OF THE CITY OF MONTGOMERY KINPAK INC. Relating to The Industrial Development Board of the City of Montgomery $4,500,000 Industrial Development Revenue Bonds (KINPAK INC. Project) Series Exhibit 99.2 SECOND RESTATED LEASE AGREEMENT between THE INDUSTRIAL DEVELOPMENT BOARD OF THE CITY OF MONTGOMERY and KINPAK INC. Relating to The Industrial Development Board of the City of Montgomery $4,500,000 Industrial Development Revenue Bonds (KINPAK INC. Project) Series 2017 Dated as of September 1, 2017 Roy S. Goldfinger, P.C. Montgomery, Alabama Bond Counsel THIS INSTRUMENT RESTATES AND REP
October 2, 2017	EX-99.4	GUARANTY AGREEMENT Exhibit 99.4 GUARANTY AGREEMENT THIS GUARANTY AGREEMENT (this “Guaranty”) is executed as of September 1, 2017, by OCEAN BIO-CHEM, INC., a Florida corporation (“OBC”), and its consolidated subsidiaries a party hereto (collectively with OBC, the “Guarantor”), in favor of REGIONS CAPITAL ADVANTAGE, INC., a Tennessee corporation (the “Lender”). Recitals A. Simultaneously with the execution and deliver
October 2, 2017	EX-99.1	UNITED STATES OF AMERICA STATE OF ALABAMA THE INDUSTRIAL DEVELOPMENT BOARD OF THE CITY OF MONTGOMERY INDUSTRIAL DEVELOPMENT REVENUE BOND (KINPAK INC. PROJECT) SERIES 2017 Exhibit 99.1 THIS BOND HAS NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT IN COMPLIANCE WITH SAID SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. UNITED STATES OF AMERICA STATE OF ALABAMA THE INDUSTRIAL DEVELOPMENT BOARD OF THE CITY OF MONTGOMERY INDUST
October 2, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2017 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File N
October 2, 2017	EX-99.3	MORTGAGE, SECURITY AGREEMENT AND ASSIGNMENT OF RENTS AND LEASES Exhibit 99.3 This instrument prepared by and upon recording return to: James L. Webb Bradley Arant Boult Cummings LLP One Federal Place 1819 5th Avenue North Birmingham, AL 35203 205-521-8808 STATE OF ALABAMA ) MONTGOMERY COUNTY ) MORTGAGE, SECURITY AGREEMENT AND ASSIGNMENT OF RENTS AND LEASES THIS MORTGAGE, security agreement and assignment of rents and leases (this “mortgage”) is made and entere
September 7, 2017	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2017 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 24, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2017 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 24, 2017	EX-99.1	Ocean Bio-Chem, Inc. Record Sales and Income for Six Month. Record sales increase 18% to $18.3 million. Net income up to $1.5 million, $0.16 per share ---- Exhibit 99.1 Ocean Bio-Chem, Inc. Record Sales and Income for Six Month. Record sales increase 18% to $18.3 million. Net income up to $1.5 million, $0.16 per share - Additional Comments by CEO Peter Dornau FORT LAUDERDALE, FL-(PRNewswire - August 21, 2017) ? Ocean Bio-Chem, Inc. (NASDAQ OBCI) announced for the six months ended June 30, 2017, net income was approximately $1,456,000, or $0.16 per co
August 15, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2017 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 15, 2017	EX-99.1	2 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Record Net Income of $953,000, Increase of 45% and Record Net Sales of $9.9 million for the Second Quarter FORT LAUDERDALE, FL-(PRNewswire - August 14, 2017) ? Ocean Bio-Chem, Inc. (NASDAQ OBCI) announced today record second quarter 2017 net income of approximately $953,000, or $0.10 per common share, compared to net income of approximately $657,000, or $0
August 14, 2017	10-Q	OBCI / Ocean Bio-Chem, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, INC. (E
July 25, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2017 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number
July 25, 2017	EX-99.1	Ocean Bio-Chem, Inc. Reports Record Nets Sales for the Second Quarter and the First Six Months of 2017 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Record Nets Sales for the Second Quarter and the First Six Months of 2017 FORT LAUDERDALE, Fl., July 24, 2017 -Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today record net sales for the second quarter and the first six months of 2017. For the second quarter of 2017, net sales were approximately $9.9 million, compared to approximately $8.7 million for the
May 22, 2017	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2017 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 16, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May15, 2017 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 16, 2017	EX-99.1	Ocean Bio-Chem, Inc. Reports Record First Quarter Net Sales of $8.4 Million; Also Reports Net Income of $504,000 and Diluted EPS of $0.05 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Record First Quarter Net Sales of $8.4 Million; Also Reports Net Income of $504,000 and Diluted EPS of $0.05 FORT LAUDERDALE, FL., May 15, 2017 -Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its first quarter 2017 financial results. The Company reported record first quarter 2017 net sales and gross profit. Net sales in the first quarter of 2017 were
May 15, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-11102 OCEAN BIO-CHEM, INC. (
April 25, 2017	EX-99.1	Ocean Bio-Chem, Inc. Reports Record First Quarter- Net Sales EX-99.1 2 f8k042417ex99ioceanbiochem.htm PRESS RELEASE, DATED APRIL 24, 2017 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Record First Quarter- Net Sales FORT LAUDERDALE, Fl., April 24, 2017 -Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today record first quarter net sales. For the first quarter of 2017 net sales were approximately $8.4 million, compared to approximately $6.8 million for the first q
April 25, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2017 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 21, 2017	DEF 14A	Ocean Bio-Chem DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)
April 5, 2017	S-8 POS	Ocean Bio-Chem POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As filed with the Securities and Exchange Commission on April 5, 2017 Registration No.
April 5, 2017	S-8 POS	Ocean Bio-Chem POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As filed with the Securities and Exchange Commission on April 5, 2017 Registration No.
April 4, 2017	8-K	Ocean Bio-Chem CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2017 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 4, 2017	EX-99.1	Ocean Bio-Chem, Inc. Reports 2016 Net Income of $2.1 Million and EPS of $0.23 Per Share Record 2016 Net Sales of $36.2 Million Exhibit 99.1 Ocean Bio-Chem, Inc. Reports 2016 Net Income of $2.1 Million and EPS of $0.23 Per Share Record 2016 Net Sales of $36.2 Million FORT LAUDERDALE, Fl., March 31, 2017 -Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its 2016 financial results. Net income for 2016 was approximately $2.1 million, compared to $461,000 in 2015, an increase of $1.6 million. Earnings per share for 2016 wer
March 31, 2017	EX-10.1	BUSINESS LOAN AGREEMENT (ASSET BASED) Exhibit 10.1 BUSINESS LOAN AGREEMENT (ASSET BASED) Principal Loan Date Maturity Bank/App Loan No. Account Officer S4,000,000.00 11/17/2016 08-31-2017 01 00230296030000000999 0023029603 K9GP4 References in the shaded area are for Lender’s use only and do no limit the applicability of this document to any particular loan or item. Any item above containing. “***” has been omitted due to text length l
March 31, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-11102 OCEAN BIO-CHEM, INC. (Exact n
March 31, 2017	EX-10.2	PROMISSORY NOTE Exhibit 10.2 REGIONS PROMISSORY NOTE Principal $4,000,000.00 Loan Date 11-17-2016 Maturity 08-31-2017 Bank/App 01 Loan No 00230296030000000999 Account 0023029603 Officer K9GP4 References in the Shaded area are for Lender’s use only and do not limit the applicability of this document to any particular loan or item. Any item above containing“***” has been omitted due to text length limitations. Borr
March 31, 2017	EX-10.3	4 Exhibit 10.3 November 17, 2016 Mr. Jeffrey Barocas Ocean Bio-Chem, Inc. 4041 S.W. 47 Ave. Ft. Lauderdale, FL 33314 Dear Jeff: The purpose of this letter is to document an agreement between Ocean Bio-Chem, Inc. and Regions Bank regarding specific terms and conditions relating to the renewal of a $4,000,000 line of credit. These terms presented below will supersede any conflicting language in the Bu
March 31, 2017	EX-21	Jurisdiction of Organization EX-21 5 f10k2016ex21oceanbiochem.htm LIST OF SUBSIDIARIES EXHIBIT 21 The following is a list of the Registrant’s subsidiaries: Name Jurisdiction of Organization Ownership % Star brite Distributing, Inc. Florida 100 Star brite Distributing Canada, Inc. Florida 100 D & S Advertising Services, Inc. Florida 100 Star brite StaPut, Inc. Florida 100 Star brite Service Centers, Inc. Florida 100 Star brite
February 24, 2017	8-K/A	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2017 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation)
February 24, 2017	EX-16.1	Tel: 954-989-7462 EXHIBIT 16.1 Tel: 954-989-7462 Fax: 954-962-1021 www.bdo.com 515 E Las Olas Blvd, 5th Floor Fort Lauderdale, FL 33301 February 23, 2017 Security and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 BDO USA, LLP (?BDO?) reviewed the draft statement provided to us VIA EMAIL, sent on February 21, 2017. BDO does not take issue with the Company?s statements regarding BDO under Item 4.01, wh
February 23, 2017	8-K	Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2017 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 18, 2016	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2016 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 14, 2016	EX-99.1	Ocean Bio-Chem, Inc. Reports Record Third Quarter Financial Results Net Sales of $12.2 million, Net Income of $1.5 million and EPS of $0.17 per/share EXHIBIT:99.1 Ocean Bio-Chem, Inc. Reports Record Third Quarter Financial Results Net Sales of $12.2 million, Net Income of $1.5 million and EPS of $0.17 per/share FORT LAUDERDALE, Fl., November 14, 2016 -Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its third quarter 2016 financial results. For the three months ended September 30, 2016, net income was approximately $1.5 million, compared to
November 14, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-11102 OCEAN BIO-CHEM, INC. (
November 14, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2016 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
October 28, 2016	8-K	Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2016 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Num
August 22, 2016	EX-16.1	[On Goldstein Schechter Koch P.A. letterhead] Exhibit 16.1 [On Goldstein Schechter Koch P.A. letterhead] August 22, 2016 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have read the paragraphs under Item 4.01 included in the Form 8-K dated August 22, 2016 of Ocean Bio-Chem, Inc. to be filed with the Securities and Exchange Commission and are in agreement with the statements contained therein, insofar as it rela
August 22, 2016	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2016 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 22, 2016	EX-16.1	[On Goldstein Schechter Koch P.A. letterhead] Exhibit 16.1 [On Goldstein Schechter Koch P.A. letterhead] August 22, 2016 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have read the paragraphs under Item 4.01 included in the Form 8-K dated August 22, 2016 of Ocean Bio-Chem, Inc. to be filed with the Securities and Exchange Commission and are in agreement with the statements contained therein, insofar as it rela
August 22, 2016	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2016 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 16, 2016	EX-99.1	2 EXHIBIT 99.1 Ocean Bio-Chem, Inc. Reports Record Second Quarter Net Income of $657,000, an increase of $543,000 over the Second Quarter of 2015 FORT LAUDERDALE, FL-(PRNewswire - August 15, 2016) – Ocean Bio-Chem, Inc. (NASDAQ OBCI) announced today second quarter net income of approximately $657,000, or $0.07 per common share, compared to approximately $114,000, or $0.01 per common share, for the s
August 16, 2016	EX-99.1	2 EXHIBIT 99.1 Ocean Bio-Chem, Inc. Reports Record Second Quarter Net Income of $657,000, an increase of $543,000 over the Second Quarter of 2015 FORT LAUDERDALE, FL-(PRNewswire - August 15, 2016) – Ocean Bio-Chem, Inc. (NASDAQ OBCI) announced today second quarter net income of approximately $657,000, or $0.07 per common share, compared to approximately $114,000, or $0.01 per common share, for the s
August 16, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2016 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction (Commission File Number) I.R.S. Employer
August 16, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2016 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction (Commission File Number) I.R.S. Employer
August 12, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-11102 OCEAN BIO-CHEM, INC. (Exact
August 12, 2016	EX-10.1	Ocean Bio-Chem, Inc. 2015 Equity Compensation Plan, as amended (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 12, 2016). Exhibit 10.1 OCEAN BIO-CHEM, INC. 2015 EQUITY COMPENSATION PLAN (as amended on July 6, 2016) The purpose of the Ocean Bio-Chem, Inc. 2015 Equity Compensation Plan (the ?Plan?) is to provide (i) employees of Ocean Bio-Chem, Inc. (the ?Company?) and its subsidiaries, (ii) certain consultants and advisors who perform services for the Company or its subsidiaries and (iii) non-employee members of the B
July 1, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported: June 29, 2016 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
June 7, 2016	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2016 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 31, 2016	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2016 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or other jurisdiction of incorporation) (Com
May 17, 2016	EX-99.1	3 EXHIBIT 99.1 Ocean Bio-Chem, Inc. Reports: 2016 First Quarter Financial Results First Quarter 2016 Net Sales Up 12 Percent from 2015 FORT LAUDERDALE, FL., May 16, 2016 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its financial results for the first quarter of 2016, including first quarter net sales of $6.75 million, a record for the first quarter and $748,000 or 12.5 percent higher than s
May 17, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2016 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
May 16, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 ¨ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-11102 OCEAN BIO-CHEM, INC. (Exac
April 29, 2016	DEF 14A	Ocean Bio-Chem DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)
March 31, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2016 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 31, 2016	EX-99.1	Ocean Bio-Chem, Inc. Declares Special Cash Dividend of $0.06 Per Share, 2015 Financial Results Reported EXHIBIT 99.1 Ocean Bio-Chem, Inc. Declares Special Cash Dividend of $0.06 Per Share, 2015 Financial Results Reported FORT LAUDERDALE, FL., March 31, 2016 -. Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today that its Board of Directors has declared a special cash dividend of $0.06 per share, payable on April 26, 2016 to holders of record of the Company's common stock on April 12, 2016. Ocean Bio-
March 30, 2016	EX-21	Jurisdiction of Organization EXHIBIT 21 The following is a list of the Registrant?s subsidiaries: Name Jurisdiction of Organization Ownership % Star brite Distributing, Inc.
March 30, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-11102 OCEAN BIO-CHEM, INC. (Exact n
January 27, 2016	SC 13G/A	OBCI / Ocean Bio-Chem, Inc. / PVAM Perlus Microcap Fund, L.P. - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) OCEAN BIO-CHEM, INC. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 674631106 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
November 16, 2015	EX-99.1	Ocean Bio-Chem, Inc. Reports Third Quarter 2015 Financial Results Record Net Sales for Three and Nine Months Ended September 30, 2015 Exhibit 99.1 Ocean Bio-Chem, Inc. Reports Third Quarter 2015 Financial Results Record Net Sales for Three and Nine Months Ended September 30, 2015 FORT LAUDERDALE, Fl., November 13, 2015 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its financial results for the three and nine months ended September 30, 2015, including record net sales.. The Company reported record net sales for the third
November 16, 2015	8-K	Ocean Bio-Chem CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2015 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 13, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 ¨ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-11102 OCEAN BIO-CHEM, INC. (
August 18, 2015	SC 13G	OBCI / Ocean Bio-Chem, Inc. / PVAM Perlus Microcap Fund, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) OCEAN BIO-CHEM, INC. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 674631106 (CUSIP Number) August 14, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
August 17, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2015 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number
August 17, 2015	EX-99.1	Ocean Bio-Chem, Inc. Reports Second Quarter 2015 Financial Results EXHIBIT 99.1 Ocean Bio-Chem, Inc. Reports Second Quarter 2015 Financial Results FORT LAUDERDALE, FL-(PRNewswire - August 14, 2015) ? Ocean Bio-Chem, Inc. (NASDAQ OBCI) announced today its operating results for the three and six months ended June 30, 2015. Net income for the second quarter of 2015 was approximately $114,000, or $0.01 per common share, compared to $411,000 or $0.05 per common share,
August 14, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 ¨ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-11102 OCEAN BIO-CHEM, INC. (Exact
June 11, 2015	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2015 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Com
June 1, 2015	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2015 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 28, 2015	EX-99.1	Ocean Bio-Chem, Inc., 2015 Equity Compensation Plan, as amended – incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016. Exhibit 99.1 OCEAN BIO-CHEM, INC. 2015 EQUITY COMPENSATION PLAN The purpose of the Ocean Bio-Chem, Inc. 2015 Equity Compensation Plan (the ?Plan?) is to provide (i) employees of Ocean Bio-Chem, Inc. (the ?Company?) and its subsidiaries, (ii) certain consultants and advisors who perform services for the Company or its subsidiaries and (iii) non-employee members of the Board of Directors of the Comp
May 28, 2015	S-8	Ocean Bio-Chem REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on May 28, 2015 Registration No.
May 18, 2015	EX-99.1	Ocean Bio-Chem, Inc. Reports First Quarter 2015 Financial Results Exhibit 99.1 Ocean Bio-Chem, Inc. Reports First Quarter 2015 Financial Results FORT LAUDERDALE, FL., May 15, 2015 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its financial results for the first quarter of 2015. Despite bad weather in much of the U.S., the Company reported a sales increase compared to the same period in 2014. The Company reported first quarter 2015 net sales of approximat
May 18, 2015	8-K	Ocean Bio-Chem CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2015 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 15, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-11102 OCEAN BIO-CHEM, INC. (Exac
April 30, 2015	DEF 14A	Ocean Bio-Chem DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)
April 1, 2015	EX-99.1	March 31, 2014 07:30 ET EXHIBIT 99.1 March 31, 2014 07:30 ET Ocean Bio-Chem, Inc. Reports Record Fourth Quarter-and Full Year 2014 Net Income Fourth quarter 2014 net income up 61%; full year 2014 net income up 40% FORT LAUDERDALE, FL., March 31, 2015 -. Ocean Bio-Chem, Inc. (NASDAQ: OBCI) reported record net income in the fourth quarter of 2014 of approximately $511,000, compared to net income of approximately $318,000 i
April 1, 2015	8-K	Ocean Bio-Chem CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2015 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 31, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-11102 OCEAN BIO-CHEM, INC. (Exact n
March 31, 2015	EX-21	Jurisdiction of Organization EXHIBIT 21 The following is a list of the Registrant?s subsidiaries: Name Jurisdiction of Organization Ownership % Star brite Distributing, Inc.
February 13, 2015	SC 13G/A	OBCI / Ocean Bio-Chem, Inc. / PVAM Perlus Microcap Fund, L.P. - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) OCEAN BIO-CHEM, INC. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 674631106 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
January 16, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2015 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Num
January 16, 2015	EX-99.1	Ocean Bio-Chem, Inc. Reports Record Fourth Quarter Sales; 2014 Top Sales Year in Company’s History EXHIBIT 99.1 Ocean Bio-Chem, Inc. Reports Record Fourth Quarter Sales; 2014 Top Sales Year in Company’s History FORT LAUDERDALE, FL., January 15, 2015 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI), today is pleased to announce all-time record fourth quarter and full year net sales for 2014. Sales for the fourth quarter of 2014 were approximately $8.7 million compared to $7.8 million in the fourth quarter
December 24, 2014	EX-99.1	Ocean Bio-Chem, Inc. CEO in Interview Sees Excellent Prospects for 2015 --Gas Price Drop Helps OBCI-- Exhibit 99.1 Ocean Bio-Chem, Inc. CEO in Interview Sees Excellent Prospects for 2015 -Gas Price Drop Helps OBCI- FORT LAUDERDALE, FL-(PR Newswire – December 23, 2014) - Ocean Bio-Chem, Inc. (NASDAQ: OBCI), said today in an interview with CEOLIVE.TV that the significant drop in gasoline prices, the Company has seen a recent increase in sales of its products to users of boats and RVs. “The drop in g
December 24, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2014 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
December 18, 2014	EX-99.1	Ocean Bio-Chem, Inc. CEO in Interview Explains Its New Disinfectant Effective and Safe against Viruses, Germs, Bacteria --Launching Product in Numerous Huge Markets-- Exhibit 99.1 Ocean Bio-Chem, Inc. CEO in Interview Explains Its New Disinfectant Effective and Safe against Viruses, Germs, Bacteria -Launching Product in Numerous Huge Markets- FORT LAUDERDALE, FL-(PR Newswire – December 18, 2014 - Ocean Bio-Chem, Inc. (NASDAQ: OBCI) said today in an interview with CEOLIVE.TV that its new product, Performacide®, kills bacteria, mold, mildew and non-enveloped viru
December 18, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2014 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 14, 2014	EX-99.1	Ocean Bio-Chem, Inc. Reports: Record Net Sales for Nine Months Ended September 30, 2014 45% Net Income Increase for Third Quarter 2014 and Record Gross Profit Exhibit 99.1 Ocean Bio-Chem, Inc. Reports: Record Net Sales for Nine Months Ended September 30, 2014 45% Net Income Increase for Third Quarter 2014 and Record Gross Profit FORT LAUDERDALE, Fla., November 14, 2014 -Ocean Bio-Chem, Inc. (NASDAQ: OBCI) announced today its operating results for the three and nine months ended September 30, 2014. For the three months ended September 30, 2014, net incom
November 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 ¨ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-11102 OCEAN BIO-CHEM, INC. (Exact name of registrant as specif
November 14, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2014 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Nu
October 21, 2014	EX-99.1	Ocean Bio-Chem, Inc., To Donate Performacide® to Countries Facing Ebola Virus Exhibit 99.1 October 20, 2014 10:30 AM EST Ocean Bio-Chem, Inc., To Donate Performacide® to Countries Facing Ebola Virus FORT LAUDERDALE, FL-(PR Newswire – October 20, 2014) – Ocean Bio-Chem, Inc. (NASDAQ:OBCI), announced today that OdorStar Technology, LLC, a wholly-owned subsidiary of Ocean Bio-Chem, Inc., is working with two organizations, Friends of Liberia, a non-profit NGO (non-governmental
October 21, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2014 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Num
September 26, 2014	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2014 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File N
August 15, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2014 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Number
August 15, 2014	EX-99.1	Ocean Bio-Chem, Inc. Reports Record Second Quarter 2014 Earnings --- Increase of 138% Exhibit 99.1 August 14, 2014 8:15 AM EST Ocean Bio-Chem, Inc. Reports Record Second Quarter 2014 Earnings - Increase of 138% FORT LAUDERDALE, FL-(PR Newswire - August 14, 2014) - Ocean Bio-Chem, Inc. (NASDAQ: OBCI), a leading manufacturer and distributor of appearance, performance, and maintenance products serving the marine, automotive, power sports, recreational vehicle and outdoor power equipme
August 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 ¨ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-11102 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified i
August 8, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2014 OCEAN BIO-CHEM, INC. (Exact name of registrant as specified in charter) Florida 0-11102 59-1564329 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
August 8, 2014	EX-99.3	August 5, 2014 Exhibit No. 99.3 August 5, 2014 Mr. Jeff Barocas Ocean Bio-Chem, Inc. 4041 S.W. 47 Ave. Ft. Lauderdale, FL 33314 Dear Jeff: The purpose of this letter is to document an agreement between Ocean Bio-Chem, Inc. and Regions Bank regarding specific terms and conditions relating to the renewal of a $6,000,000 line of credit. These terms presented below will supersede any conflicting language in the Busi
August 8, 2014	EX-99.1	BUSINESS LOAN AGREEMENT (ASSET BASED) Exhibit No. 99.1 BUSINESS LOAN AGREEMENT (ASSET BASED) Principal $6,000,000.00 Loan Date 08-04-2014 Maturity 07-06-2016 Bank/App 01 Loan No 00230296030000000999 Account 0023029603 Officer MSJ01 References in the shaded area are for Lender’s use only and do not limit the applicability of this document to any particular loan or item. Any item above containing “***” has been omitted due to text lengt
August 8, 2014	EX-99.2	PROMISSORY NOTE Exhibit 99.2 PROMISSORY NOTE Principal Loan Date Maturity Bank/App Loan No Account Officer $6,000,000.00 08-04-2014 07-06-2016 01 00230296030000000999 0023029603 MSJ01 References in the shaded area are for Lender’s use only and do not limit the applicability of this document to any particular loan or item. Any item above containing “***” has been omitted due to text length limitations. Borrower: O

OBCI / Ocean Bio-Chem, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)